Implantable neurostimulation therapy for chronic gastroparesis
Enterra Medical manufactures Enterra Therapy, an FDA-approved implantable device for treating chronic nausea and vomiting caused by gastroparesis. The engineering stack—C/C++, C#, Python, MATLAB/Simulink, and embedded RTOS—reflects a medtech firmware and signal-processing focus. Active projects span next-generation implants, closed-loop therapy integration, and custom ASIC development, signaling iterative hardware advancement. Manufacturing and regulatory compliance rank equally with engineering in hiring priority, a pattern typical of device companies scaling from pilot to production.
Enterra Medical is a Minneapolis-based medical device manufacturer founded in 2022, focusing exclusively on gastroparesis treatment. The company owns Enterra Therapy, an implantable gastric electrical stimulation device approved under FDA Humanitarian Device Exemption since 2000; over 15,000 patients have received the implant. The product is positioned for patients aged 18–70 with diabetic or idiopathic gastroparesis who do not respond to pharmacological intervention. Operations span clinical evidence generation, surgical training for gastroenterologists, patient recruitment, and manufacturing scale-up—reflected in hiring across engineering, healthcare, product, and manufacturing functions.
Enterra Therapy is an implantable neurostimulation device for reducing chronic nausea and vomiting in patients with diabetic or idiopathic gastroparesis who have not responded to medication. Over 15,000 patients have received the implant.
Firmware and signal processing are built on C/C++, C#, Python, MATLAB, and Simulink. Development uses GitHub and Jira; embedded systems run on RTOS. BLE enables wireless device communication.
Other companies in the same industry, closest in size